U.S. markets closed

Kuke Music Holding Limited (KUKE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W
6.12+0.09 (+1.49%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close6.03
Open6.00
Bid5.96 x 800
Ask6.06 x 1200
Day's Range5.92 - 6.19
52 Week Range4.55 - 15.06
Volume15,266
Avg. Volume55,046
Market Cap180.948M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateMay 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-42% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kuke Music Holding Limited
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Motley Fool

    Kuke Music Holding Limited (KUKE) Q2 2021 Earnings Call Transcript

    Image source: The Motley Fool. Kuke Music Holding Limited (NYSE: KUKE)Q2 2021 Earnings CallAug 04, 2021, 7:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning and good evening, ladies and gentlemen.

  • PR Newswire

    Kuke Reports Second Quarter 2021 Unaudited Financial Results

    Kuke Music Holding Limited ("Kuke" or the "Company") (NYSE: KUKE), a leading provider of classical music content, licensing, subscription, and smart music learning solutions in China, today announced its unaudited financial results for the second quarter ended June 30, 2021.

  • PR Newswire

    Kuke Announces Strategic Cooperation Agreement with People's Music Publishing House

    Kuke Music Holding Limited (NYSE: KUKE) ("Kuke" or the "Company"), a leading classical music content provider and AI-driven music education company in China, today announced a strategic cooperation agreement with People's Music Publishing House ("People's Music"). The two parties will work together to establish the People's Music & Naxos Global Platinum Record Program of China, and the Global Resource Co-construction Plan for the National Aesthetic Education Research Music Encyclopedia Interdisc